Across TCGA pan-cancer cohorts, HSF2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSF2 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HSF2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HSF2 expression acts as an unfavorable survival marker.
HNSC, LUSC, and LUAD are the cancer types where HSF2 Mutation most reproducibly stratifies survival.